Rationale: Neovascularization favors intraplaque hemorrhage and plaque rupture. Development of therapeutic strategies against atheromatous angiogenesis requires elucidation of its initiating factors.
I ntraplaque angiogenesis is a prominent feature of advanced atherothrombotic lesions, and accumulating evidence suggests that it contributes to intraplaque hemorrhage and leukocyte infiltration, two processes that are intimately associated with a high risk of plaque rupture. [1] [2] [3] [4] [5] Although neovascularization is often associated with late stages of plaque development, several studies have reported the presence of thin-walled microvessels in early lesions of human atheromatous carotid and coronary arteries, indicating that angiogenesis is stimulated during the initial steps of atheroma formation. 6, 7 However, the mechanisms responsible for the initiation of human atheroma-associated angiogenesis are unknown.
Hypoxia is among the strongest known angiogenic stimuli and recently, the presence of hypoxia was detected in advanced human carotid atherosclerotic lesions, suggesting its potential involvement in the regulation of intraplaque angiogenesis. 8 However, hypoxia in atherosclerotic arteries was shown to be restricted to phagocyte-rich regions within the most complicated lesions. 8 Although hypoxia may stimulate angiogenesis in the most advanced stages of the disease, other microenvironmental factors are likely to regulate atheromatous angiogenesis at the earlier stages of atheroma formation when intramedial angiogenesis can already be observed despite the putative absence of hypoxia. Studies in animal models of atherosclerosis have shown that hypercholesterolemia enhances vasa vasorum neovascularization in the aortic adventitia and outer media and in coronary arteries before the development of vascular lesions. 9, 10 Therefore, lipid deposition in the arterial wall, the key initiating event in atherogenesis, 11 may directly trigger the angiogenic response during the first stages of the atheromatous process.
Smooth muscle cells (SMCs), the predominant cell type found in the arterial wall, retain substantial phenotypic plasticity and can promote intramural pathological processes in response to injurious microenvironmental factors. For example, SMCs undergo profound changes in their phenotype during neointimal formation in response to vessel injury. 12 We hypothesize that, similarly, SMCs may acquire a proangiogenic phenotype and contribute to the induction of neovascularization in atheromatous arteries. Supporting this hypothesis, in vitro studies have shown that SMCs can express vascular endothelial growth factor-A (VEGF-A), and that conditioned medium from SMCs stimulates the formation of capillary-like structures by endothelial cells. 13, 14 In the present study, we characterized angiogenesis in early human atheroma and investigated the potential contribution of SMCs and atheroma-derived lipids to this process. Our results show that VEGF-A production is enhanced in medial SMCs of early atheromatous aortas, suggesting that they contribute to the initiation of the angiogenic response to atheroma formation. We further demonstrate in vitro, using human SMCs and atheromatous tissues and in vivo in a mouse model of angiogenesis, that atheroma-derived lipid activators of peroxisome proliferator-activated receptor-␥ (PPAR-␥) are potent inducers of this phenotypic change.
Methods

Tissue Samples
Forty human infradiaphragmatic aortic segments, each harvested from a different donor after organ transplantation with the authorization of the French Biomedicine Agency (authorization number PFS09-007), were included in this study. The investigation conforms to the principles outlined in the Declaration of Helsinki. A detailed description of the sample preparation is given in the Online Supplement, available at http://circres.ahajournals.org.
Cell Culture
Tunica media were dissected from human aortas and digested with 0.3% collagenase (Invitrogen, Paisley, UK) and 0.1% elastase (Worthington, Lakewood, NJ) for 3 hours at 37°C. Human aortic SMCs were then collected after filtration through 100-and then 40-m Nylon filters, and cultured in smooth muscle cell medium (Promocell, Heidelberg, Germany) containing 5% fetal calf serum (FCS), gentamicin-sulfate (50 mg/mL), amphotericin B (50 g/mL), insulin (5 mg/mL), and human epidermal and fibroblast growth factors (0.5 and 2 g/mL, respectively). Absence of contamination by myeloid cells in primary cultures was confirmed by immunostaining for the monocyte/macrophage markers CD68 and calprotectin. For in vitro stimulation experiments, only SMCs isolated from healthy human aortas devoid of atheromatous lesions were used. Mouse aortic SMCs were prepared as described previously with minor modifications (see Online Supplement). 15
Immunohistology of Human Aortas
Frozen aortas were cryosectioned at 6 m, and sections were fixed in formalin and stained for lipids with Oil red O. Tissues fixed in 3.7% paraformaldehyde were embedded in paraffin and sectioned at 6 m. Sections were stained with Perls Prussian blue for hemosiderin and with Masson trichrome for fibrous tissue and general morphology. Immunostaining was performed as described in Online Supplement Methods.
Quantitative Real-Time PCR
Total RNA extraction from pulverized tissues and from cultured human aortic SMCs for real-time fluorescence PCR analysis was performed as described in the Online Supplement.
Measurement of VEGF-A, VEGF-C, Placental
Growth Factor, Platelet-Derived Growth Factor-AA, 15-Deoxy-⌬12,14-Prostaglandin J2, and Thiobarbituric Acid-Reactive Substance Levels Also see the Online Supplement for description of laser microdissection and isolation and oxidation of low-density lipoproteins.
Implantation of Matrigels
After an overnight incubation of mouse aortic SMCs in 75-cm 2 culture flasks with a mixture of intimal lesion-conditioned medium and serum-free cell culture medium (1:8 vol/vol) or with 20 mol/L rosiglitazone, the cells were washed, trypsinized and resuspended at 300ϫ10 3 cells in 100 L DMEM (Invitrogen), mixed on ice with 150 L of growth factor-depleted Matrigel (high concentration, BD Biosciences), and injected subcutaneously into C57Bl/6J recipient mice (purchased from Janvier, Le Genest-Saint-Isle, France).
Immunohistology of Mouse Matrigels
Matrigel plugs fixed in zinc-fixative (100 mmol/L Tris-HCl containing 37 mmol/L zinc chloride, 23 mmol/L zinc acetate, 3.2 mmol/L calcium acetate) were embedded in paraffin and sectioned at 6 m. For immunofluorescent staining, Matrigel sections were permeabilized with 0.1% Triton X-100 in 0.1 mol/L citrate buffer pH 6.0, and immunostaining for endothelial cells was performed using a rat monoclonal antibody to mouse CD31 (clone 390, BD Biosciences) and counterstained with DAPI.
Determination of Matrigel Hemoglobin Content
Matrigel plugs were excised from euthanized animals, weighed, homogenized in PBS, and centrifuged, and hemoglobin/heme concentration of supernatants was measured by addition of formic acid and absorbance reading at 405 nm.
Statistics
Data represent meanϮSEM, and statistical differences were determined using the Wilcoxon test for paired data and the Mann-Whitney test for unpaired data, as appropriate, except for the comparisons of
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Results
Early Aortic Atheromatous Lesions Are Associated With Intramedial Growth of Structurally Fragile Blood Vessels
To study the initial steps of atheroma-associated angiogenesis, 40 human abdominal aortic segments, each harvested from a different organ donor, were analyzed for the presence of early atheromatous lesions. Among 40 aortic samples, 19 were devoid of grossly visible signs of lesions and were classified as healthy, whereas all other samples showed macroscopic features of early lesions, such as yellow fatty streaks and/or white areas of intimal proliferation, and were then classified as atheromatous aortas (Online Figure I, A) . Further characterization of the samples by Oil red O and Masson trichrome staining showed that lesions of atheromatous aortas corresponded to fatty streaks or to more advanced fibrolipidic lesions with intimal lipid deposits and fibrous proliferation (Online Figure I , B and C). Intimal thickening was observed in both fatty streaks and fibrolipidic lesions as indicated by their increased intima/media ratios compared with healthy aortas (0.45Ϯ0.04 for fatty streaks, 1.83Ϯ0.15 for fibrolipidic lesions, and 0.08Ϯ0.01 for healthy aortas; PϽ0.0003, healthy versus fatty streaks, and PϽ0.0001, healthy versus fibrolipidic lesions). Using immunostaining procedures for blood vessels and mural cells, we investigated the localization, density, and mural cell coverage of microvessels in atheromatous aortas. Blood neovessels, identified by CD31 staining, were found in the intima of 12 of 21 atheromatous aortas (2 of 10 fatty streaks and 10 of 11 fibrolipidic lesions). Even when the intimal lesion was devoid of neovessels, the microvessel density was systematically increased in medial layers subjacent to both fatty streaks and fibrolipidic lesions compared with media from healthy aortas ( Figure 1A and 1B). No difference in medial thickness was found between healthy and fatty streak-bearing aortas (1.34Ϯ0.09 mm for healthy aortas versus 1.31Ϯ0.15 mm for fatty streaks, Pϭ0.525). A significant decrease in medial thickness was even found in aortas bearing fibrolipidic lesions compared with healthy and fatty streak-bearing aortas (1.34Ϯ0.09 mm for healthy aortas versus 0.81Ϯ0.25 mm for fibrolipidic aortas, PϽ0.0005). This result shows that the increased intramedial vascularization of atheromatous aortas is due to an active angiogenic process and not to an increased medial thickness compared with healthy aortas.
Notably, medial microvessels originating from the adventitia extended much deeper toward the intima in atheromatous aortas than in healthy aortas ( Figure 1A ). In fact, whereas in all healthy aortas, medial microvessels were exclusively localized in the outer quarter of the media, next to the adventitial border, microvessels located outside this zone of the media were observed in 16 of 21 aortas bearing fatty streaks and/or fibrolipidic lesions ( Figure 1A ). These more inner medial microvessels showed a reduced coverage with ␣-smooth muscle actin-positive cells as compared with microvessels located in the outer medial zone of healthy and atheromatous aortas ( Figure 1C and 1D). The poor mural cell coverage of inner medial microvessels was similar to that of vessels within lesions ( Figure 1D ) and indicates that these vessels are structurally vulnerable.
Networks of fragile neovessels have been shown to contribute to intraplaque hemorrhage in advanced atherosclerotic lesions. 3 For this reason, we investigated whether angiogenesis-associated hemorrhage occurred also in early atheromatous aortas. Recent and/or old erythrocyte extravasation in fatty streaks and early fibrolipidic lesions and subjacent media was explored by immunostaining of the erythrocyte antigen glycophorin A and by Prussian blue staining for ferric iron. Extravasated erythrocytes were not detected in any of the fatty streak lesions and were found in 4 out of the 11 fibrolipidic lesions. Of note, extravasated erythrocytes were found in the vicinity of thin-walled, venule-like intimal neovessels within lesions but not in subjacent medias ( Figure 2 ).
Taken together, these data suggest that the growth of a vulnerable blood vascular network is a prominent early event during the atheromatous process that is initiated in the media subjacent to lesions. It is of note that in contrasts to blood vessels, no lymphatics were found in medial layers of either healthy or early atheromatous aortas, as assessed by podopla-nin immunostaining (not shown), suggesting that, at least during the early stages of atheroma formation, the medial layer is not an active site of lymphangiogenesis.
VEGF-A Production by Medial SMCs Is Enhanced in Early Atheromatous Aortas
The increased intramedial microvessel density and the presence of inner medial microvessels in aortas bearing fatty streaks and fibrolipidic lesions strongly suggest that the expression of proangiogenic factors in the arterial wall is upregulated early during the atheromatous process. To test this possibility, when sufficient material was available, intimal lesions and medial layers of aortas bearing fatty streaks and/or fibrolipidic lesions were separated by dissection (Online Figure II) , and their VEGF-A and VEGF-C protein contents were compared with that of healthy aortas by ELISA. The separation and the absence of crosscontamination between the two layers were confirmed by histological analysis (Online Figure II) . No difference in VEGF-C protein levels per gram tissue were found between healthy aortas and medial and intimal layers of atheromatous aortas (Online Figure III, A) , indicating that VEGF-C production is not upregulated in early atheromatous aortas. In contrast, whereas VEGF-A protein levels per gram tissue were similar in tissue-culture medium of early intimal lesions and of healthy aortas, it was significantly increased in medial layers of atheromatous aortas compared with both healthy aortas and intimal lesions ( Figure 3A ). Furthermore, real-time PCR analysis of mRNA extracted from 8 healthy aortas and 10 media of atheromatous aortas showed that the VEGF-A/ GAPDH mRNA ratios were significantly higher in medial layers from atheromatous aortas than in healthy aortas (Figure 3B) . These results show that VEGF-A expression is enhanced at both the protein and mRNA levels in early atheromatous aortas and that it mostly originates from their medial layer. Supporting this hypothesis, positive immunostaining for VEGF-A was detected mostly in the medial layer and to a much lesser extent, in intimal lesions of atheromatous aortas ( Figures 3C and 4C) . A faint positive staining for VEGF-A was observed in the medial layer of all healthy aortas (not shown), suggesting that although produced at a lower level than in atheromatous aortas, VEGF-A is also expressed within the medial layer of healthy aortas. To determine the cellular origin of VEGF-A in atheromatous aortas, immunostaining for VEGF-A was combined to staining of SMCs, endothelial cells, lymphocytes, or phagocytes.
No T-or B-lymphocytes were detected in early atheromatous aortas (not shown). The vast majority of the intramedial cells of atheromatous aortas were positive for VEGF-A (88.8Ϯ4.2% of total nucleate cells, nϭ8 sections, each from a different atheromatous aorta), and for the SMC markers calponin and smooth muscle myosin heavy chain (MHC) (94.3Ϯ2.2% and 93.3Ϯ2.4% of total nucleate cells, respectively), while negative for the phagocyte and myeloid markers CD68 and calprotectin (2.6Ϯ0.7% and 2.3Ϯ0.9% total nucleate cells, respectively) ( Figure 4A -C), indicating that VEGF-A predominantly originates from medial SMCs. VEGF-A-expressing cells within intimal lesions included cells positive for markers of smooth muscle cells ( Figure 4A through 4C), macrophages ( Figure 4A through 4C ), or endothelial cells (not shown). To further characterize the presumed proangiogenic medial SMCs in atheromatous aortas, medial cells from 4 healthy and 4 atheromatous aortas were precisely isolated by laser microdissection and compared for mRNA expression of the smooth muscle lineage markers, smooth muscle 22-␣ (SM22-␣) and smoothelin, the angiogenic factors, VEGF-A and VEGF-C, the monocyte chemotactic protein-1 (MCP-1), and the marker of phagocytic activity, CD68. Confirming the smooth muscle lineage of the microdissected cells, all healthy and atheromatous samples were positive for expression of smoothelin and sm22-␣ transcripts, without any difference in the mRNA expression level between the two groups (Online Figure IV) . The level of VEGF-A transcript was significantly higher in medial SMCs from atheromatous aortas (Online Figure IV) , confirming the overexpression of VEGF-A by these cells compared with medial SMCs from healthy aortas. Despite a trend toward higher MCP-1 mRNA levels in atheromatous medial SMCs, no statistically significant difference in mRNA levels was found between medial SMCs from healthy and atheromatous aortas for the other genes tested (Online Figure IV) . This suggests that the phenotypic change in medial SMCs of atheromatous aortas may be rather subtle than profound and generalized.
Placental growth factor (PlGF) is a homologue of VEGF-A that stimulates angiogenesis and was previously shown to be expressed in advanced human atherosclerotic lesions. A slight increase in PlGF level was found in intimal lesions but not medial layers, of early atheromatous aortas compared with healthy aortas (Online Figure III, B) . However, the protein level of PlGF in intimal lesions was much lower than that of VEGF-A in the subjacent medial layers (3.36 ng/g tissue and 29.36 ng/g tissue, respectively), suggesting that VEGF-A may play a predominant role in the initiation of the intramural angiogenic response during the initial stages of atherogenesis. Altogether, these results suggest that the initiation of atheromatous angiogenesis does not only rely on the production of proangiogenic factors by intraplaque cells but also involves production of VEGF-A by medial SMCs. Remarkably, cultured SMCs isolated from medial layers of atheromatous arteries secreted higher baseline levels of VEGF-A than cultured SMCs isolated from medial layers of healthy aortas (74.3Ϯ32.9 versus 395.1Ϯ88.2 pg/mL, PϽ0.02, nϭ5 healthy aortas, 4 atheromatous aortas). The fact that the increased production of VEGF-A by medial SMCs of atheromatous aortas persists after culturing indicates that it corresponds to a sustained phenotypic change in these cells associated with early atheroma.
Lipids Derived From Early Atheromatous Lesions Stimulate VEGF-A Production by Healthy Human Aortic SMCs in a PPAR-␥-Dependent Manner
The enhanced production of VEGF-A by medial SMCs of atheromatous aortas suggests that microenvironmental factors associated with the presence of an intimal lesion cause proangiogenic phenotypic alterations in the subjacent medial SMCs. To address the possible contribution of hypoxia to the increased VEGF-A expression within medial SMCs of early atheromatous aortas, we performed immunostaining for hypoxia-inducible transcription factor 1␣ (HIF1␣), the subunit of the hypoxia sensor HIF1 that is rapidly degraded in the presence of oxygen but stabilized during hypoxia. In contrast to VEGF-A that was principally found within medial layers of atheromatous aortas (Figure 4 ), positive immunostaining for HIF-1␣, when present, was restricted to intimal lesions (Online Figure V, A) . Furthermore, no significant difference in intramedial HIF-1␣ mRNA levels measured by real-time PCR was found between healthy and atheromatous aortas (Online Figure V, B) . These results show that HIF-1␣ is neither stabilized nor upregulated in medial SMCs of early atheromatous aortas, suggesting that hypoxia does not contribute, at least directly, to their enhanced VEGF production. To determine whether early intimal lesions contain soluble inducer(s) of VEGF-A expression, we measured the effect of conditioned medium from healthy aortas and from the intimal and medial layers of atheromatous aortas on VEGF-A production by medial SMCs isolated from healthy human thoracic aortas. Levels of VEGF-A secreted by cultured healthy human aortic SMCs remained unchanged after incubation with conditioned medium from healthy aortas ( Figure 5A ). However, incubation of these cells with conditioned medium from intimal lesions markedly amplified their VEGF-A production at both the RNA and protein levels ( Figure 5A and 5B). This shows that early atheromatous lesions contain soluble inducers of VEGF-A expression. Of note, the increased production of VEGF-A by SMCs after a single overnight pulse incubation with intimal lesion-conditioned medium extended up to 7 days (not shown), indicating that exposure of SMCs to intimal lesion-derived soluble factors induces a sustained phenotypic change in these cells. Conditioned medium from the medial layer of atheromatous aortas also induced VEGF-A expression in healthy SMCs, but to a lesser extent than conditioned medium from intimal lesions (Figure 5A and 5B ). This suggests that the media adjacent to intimal lesions also contains soluble inducers of VEGF-A expression that may have diffused and been convected outward from the lesion.
Platelet-derived growth factor-AHA (PDGF-AA) was shown to be a potent inducer of VEGF-A expression. 16, 17 For this reason, we determined whether intimal lesions were enriched in PDGF-AA or in soluble factors able to stimulate its expression by medial SMCs. PDGF-AA protein levels were similar in healthy aortas and in intimal lesions and medial layers of atheromatous aortas (Online Figure VI, A) , and PDGF-AA production by cultured SMCs was enhanced to a similar extent by conditioned medium from healthy and from intimal lesions (Online Figure VI, B) . Thus, the increased VEGF-A-expression promoting effect of conditioned medium of intimal lesions compared with that of healthy aortas is independent of the PDGF-AA pathway.
Previous studies have established that a variety of lipids present in atheromatous lesions, including lipid components of oxidized low-density lipoproteins, oxidized phospholipids, and eicosanoids, can promote VEGF-A production in endothelial cells, macrophages, and SMCs. 18 -21 Therefore, we hypothesized that the soluble lesion-derived VEGF-Aenhancing factors were lipids. To examine this hypothesis, we used 1-butanol to extract lipids from lesion-conditioned medium. The protein migration pattern of lesion-conditioned medium was unaffected by delipidation with 1-butanol, which, however, resulted in a 90% decrease in cholesterol content of conditioned medium, indicating a successful delipidation process (Online Figure VII) . The enhancing effect of lesion-conditioned medium on VEGF-A production by SMCs was resistant to heat denaturation but was dramatically attenuated by delipidation, indicating a lipid mediator ( Figure  5C ). Confirming the lipid nature of the soluble lesion-derived VEGF-A expression-inducer(s), the isolated lipid fraction fully reproduced the stimulating effect of lesion-conditioned medium on VEGF-A production by SMCs ( Figure 5C ).
Figure 5. Soluble lipids derived from early atheroma stimulate VEGF-A expression by healthy human aortic SMCs. A,
VEGF-A protein levels secreted by healthy human aortic SMCs incubated or not with tissue-conditioned medium of healthy or atheromatous aortas. The baseline VEGF-A values of the tissueconditioned medium used for stimulation were subtracted from the VEGF-A levels measured in culture supernatants. B, VEGF-A mRNA levels in cultured healthy human aortic SMCs incubated or not with healthy or atheromatous aortic tissue-conditioned medium. Bar graphs show the relative VEGF-A expression after normalization to the GAPDH gene expression. The control value of untreated cells was set at 1 to calculate the relative signal in conditioned medium-treated cells. #Significant difference from the control group (PϽ0.02). C, VEGF-A protein levels in culture supernatant of healthy human aortic SMCs incubated with untreated, heat-denaturated, or with the lipid or protein fractions of conditioned medium from the lesion part of atheromatous aortas. #Significant difference from the control group (PϽ0.02).
PPAR-␥ is a nexus of lipid signaling and an active transcription factor in the vessel wall that is expressed by both SMCs and endothelial cells. 22, 23 Importantly, activators of PPAR-␥ were shown to upregulate the expression of VEGF-A in SMCs. 22 We found that conditioned medium from early atheromatous lesions was enriched in endogenous activators of PPAR-␥, including 15-deoxy-⌬12,14-prostaglandin J2 (15d-PGJ2), oxidized lipids, and their derivatives, estimated by measurement of thiobarbituric acid reactive substances (TBARS) ( Figure 6A and 6B) . Treatment of SMCs with the PPAR-␥ inhibitor GW9662 or with a blocking antibody to 15d-PGJ2 resulted in a dose-dependent decrease in the VEGF-A production enhancing effect of lesionconditioned medium ( Figure 6C and 6D) , indicating that PPAR-␥ agonists contribute to the stimulating effect of conditioned medium from intimal lesion on VEGF-A production by SMCs. Furthermore, we found that the PPAR-␥ pathway was upregulated in the medial layer of atheromatous aortas, as indicated by their increased PPAR-␥/GAPDH mRNA ratio compared with that of healthy aortas ( Figure  6E ). Altogether, these results suggest that lesion-derived PPAR-␥ agonists including 15d-PGJ2 stimulate VEGF-A production by medial SMCs in atheromatous aortas.
SMCs Exposed to Atheromatous Lesion-Derived Activators of PPAR-␥ Can Orchestrate an Angiogenic Response In Vivo
The increased VEGF-A production by SMCs exposed to lesion-conditioned medium suggests that these cells could orchestrate the growth of a vascular network. Mouse SMCs displayed a VEGF-A response pattern similar to that of human SMCs, with an increased VEGF-A secretion after incubation with lesion-conditioned medium that was prevented by the PPAR-␥ inhibitor GW9662 (Online Figure  VIII, A) . The angiogenic activity of control and lesionconditioned medium-prestimulated mouse SMCs was then assessed in vivo in the Matrigel implant assay. After an overnight pulse incubation of SMCs with RPMI or lesionconditioned medium, the incubation medium was discarded and SMCs were washed with PBS before being mixed with growth factor-depleted Matrigel. Matrigels were then either cultured in vitro in serum-free culture medium for analysis of VEGF-A production over time or implanted in mice for assessment of their angiogenic activity 10 days later. Measurement of VEGF-A levels in Matrigel culture supernatants harvested and replaced with fresh medium every 2 days, showed that VEGF-A secretion was increased in Matrigels containing stimulated SMCs compared with Matrigels containing control SMCs, and that this increase extended up to 10 days after initial exposure to lesion-conditioned medium (Online Figure VIII, B and C) . This shows that the increase in SMC VEGF-A production induced by lesion-derived soluble factors persists even after the initial stimulus is gone. Analysis of the Matrigels implanted in mice showed that whereas empty Matrigels and Matrigels containing nonstimulated SMCs displayed a translucid appearance at macroscopic observation, Matrigels containing SMCs that had been prestimulated with lesion-conditioned medium appeared dark and bloody, suggesting increased vascularization ( Figure 7A and 7B). Immunohistological analysis confirmed the presence of red blood cell (RBC)-filled spaces and vessels in Matrigels containing SMCs prestimulated with lesion-conditioned medium (not shown). Furthermore, the degree of vascularization of the Matrigel plugs, estimated by CD31 staining and by measurement of their hemoglobin content, was considerably increased in Matrigels containing SMCs prestimulated with lesion-conditioned medium compared with Matrigels containing unstimulated SMCs ( Figure 7C and 7D) . Notably, the degree of vascularization of Matrigels containing SMCs that had been incubated with lesion-conditioned medium in the presence of GW9962 was similar to that of Matrigels containing unstimulated cells, indicating that blockade of the PPAR-␥ pathway inhibits lesion-conditioned mediuminduced increased angiogenic activity of SMCs ( Figure 7A through 7D). In contrast, SMCs prestimulated with the synthetic PPAR-␥ agonist, rosiglitazone, before implantation in Matrigels, mimicked the proangiogenic effect of SMCs prestimulated with lesion-conditioned medium ( Figure 7A and 7B). It is of note that the proangiogenic activity of exogenous VEGF in Matrigels containing either control or GW9662 pre-exposed SMCs was similar (Online Figure IX) , showing that GW9662-exposed SMCs do not interfere with VEGF-A-induced angiogenesis. Taken together, these results provide a proof of concept that exposure of SMCs to atheroma-derived activators of PPAR-␥ or to rosiglitazone turns those cells into potent orchestrators of angiogenesis in vivo.
Discussion
In the present study, we characterized angiogenesis and investigated the role of medial SMCs and lesion-derived soluble lipid mediators in its initiation during the early stages of human atheroma formation. Our results show that intramedial angiogenesis is an early event of the atheromatous process that precedes intimal neovascularization. In fact, we found that even when intimal fatty streaks and fibrolipidic lesions were devoid of neovessels, the vessel density and invasiveness into the medial layers subjacent to these lesions were systematically increased compared with that of healthy aortas. These data support the generally accepted idea that plaque neovascularization is a centripetal process that arises principally from adventitial vasa vasorum located vis-à-vis atherothrombotic lesions, and extends into the intimal layer through the media. 24, 25 It has been shown that neovessels in complicated lesions are structurally vulnerable due to a lack of associated mural cells. 3, 6, 26 Similarly, we observed that intimal and medial neovessels in early atheromatous aortas were also characterized by poor coverage with mural cells. This could indicate that these neovessels have not reached their final maturity state and/or that they are more of a capillary or postcapillary venous nature, rather than of arterial nature. Previous studies have shown the association between vessel immaturity and the occurrence of microhemorrhages and hematoma within complicated atherosclerotic lesions, suggesting that neovessel fragility may cause intraplaque hemorrhage. 3, 26 However, we show that the presence of thin-walled neovessels within the medial layer of early atheromatous aortas was not associated with intramedial deposition of extravasated erythrocytes and hemosiderin. This indicates that the growth of an immature capillary-like vascular network is not sufficient to cause intramural hemorrhage in atherothrombosis. We have shown previously that hemorrhagic complicated plaques are not only enriched in fragile vessels but also in leukocytes and protease activity that may contribute to the development of a vascular injury-prone and hemorrhage-prone environment in those lesions. 3, 27 Thus, it is conceivable that in addition to neovessel fragility, factors capable of degrading the basal lamina are required to lead to the hemorrhagic phenotype.
Our study further shows that in addition to being an active site of angiogenesis, the medial layer is the major source of VEGF-A in human aortas bearing early atheromatous lesions, pointing to a role for medial cells in promoting atheromatous angiogenesis. Experiments in mice have shown that myeloid cells can give rise to smooth muscle-like cells and contribute to vascular inflammation within neointimal lesions of injured arteries. 28 These myeloid-derived smooth muscle-like cells were shown to be positive for markers of both macrophages and SMCs. 28 In contrast, we found that the VEGF-Aexpressing cells in medial layers of human atheromatous aortas were positive for smooth muscle markers, including smooth muscle MHC, the most stringent marker of the smooth muscle lineage, 29 -31 while negative for macrophage markers, showing their smooth muscle identity. Importantly, SMCs isolated from medial layers of early atheromatous arteries secreted higher baseline levels of VEGF-A in culture than SMCs isolated from healthy aortas, indicating that a sustained phenotypic change is induced in SMCs cells during the initial stages of atheroma formation. These results suggest that increased VEGF-A production by medial SMCs contribute to the initiation of the angiogenic response in human atheromatous aortas. Interestingly, the ability of SMCs overexpressing VEGF-A to stimulate intramural angiogenesis was previously shown in a model of arterial gene transfer in rabbits. 32 Previous studies have assessed the presence of hypoxia, one of the strongest known angiogenic stimuli, in arteries of rabbits with hypercholesterolemia-induced atherosclerosis 33 and in human carotid arteries with advanced atherosclerotic lesions. 8 These studies have revealed the existence of hypoxic regions in phagocyte-rich regions within thick intimal lesions but not in the subjacent medial layers. 8, 33 Thus, intramedial hypoxia is unlikely to explain the increased VEGF-A production by medial SMCs in atheromatous aortas. Consistent with this hypothesis, we found that the hypoxia-stabilized HIF-1␣ protein was absent of medial layers of atheromatous aortas. Taken together, these data suggest that microenvironmental factors others than hypoxia are responsible for the enhanced VEGF-A expression of medial SMCs from early atheromatous aortas. Several in vitro studies have shown that different classes of soluble phospholipids, eicosanoids and components of oxidized LDL found in atheromatous lesions upregulate VEGF-A in various cell types, including SMCs. 19 -22 We found that lipid oxidation products and the eicosanoid 15d-PGJ2 were enriched in atheromatous aortas. For this reason, we postulated that exposure of medial SMCs to soluble lipid mediators convected from intimal lesions toward the subjacent medial layer might contribute to stimulate VEGF-A production in these cells. Supporting this hypothesis and providing an in vivo proof of concept, we show that the soluble lipid fraction of human atheromatous lesion supernatants induced a sustained increase in VEGF-A production by cultured healthy human and mouse SMCs that persisted for several days after removal of the stimulus, and that mouse SMCs exposed to lesion-conditioned medium acquired a strong proangiogenic phenotype and promoted neovascularization of Matrigel implants in mice. It is of note that Matrigel implants containing SMCs pre-exposed to lesion conditioned medium did not only display increased vascularization but also hemorrhage. This was in contrast with the absence of RBC leakage from intramedial neovessels in early atheromatous aortas. It is possible that the acute nature of the Matrigel model, leading to an exacerbated angiogenic response in a leukocyte-rich environment due to leukocyte infiltration accompanying the implantation of foreign bodies represented by the implants, have contributed to favor RBC extravasation from neovessels within plugs.
We also report that the stimulating effect of lesion supernatants on VEGF-A production by human aortic SMCs is, at least in part, mediated by PPAR-␥ and its endogeneous ligand, 15d-PGJ2. 15d-PGJ2 was previously shown to be expressed within intimal lesions by CD68-positive foam cells, 21 suggesting the potential contribution of foam cells to the generation of PPAR-␥ agonists within intimal lesions of atheromatous aortas. How the increase in VEGF-A expression induced by lesion-derived lipid factors in SMCs is maintained over time remains to be determined, but, interestingly, PPAR-␥ agonists were shown to induce the production of PGD2, the metabolic precursors of 15d-PGJ2, in SMCs, suggesting the possibility for a self-perpetuating mechanism. 34 Furthermore, we show that the synthetic PPAR-␥ agonist rosiglitazone, a thiazolidinedione widely used to treat patients with type 2 diabetes, reproduced the triggering effect of lesion-conditioned medium on VEGF-A production and enhancement of angiogenesis by SMCs. This is in contrast with the results by Gealekman et al showing the absence of proangiogenic effect of rosiglitazone on mouse aortic rings, 35 a result presumably due to the suppressing effect of PPAR-␥ activation on endothelial cells proliferation and differentiation into tube-like structures. 36 -39 However, in the same study, the authors showed that rosiglitazone turns to be a potent activator of angiogenesis when added onto epididymal fat pad explants, through its ability to upregulate VEGF-A expression in adipocytes. These findings underline the fact that the effects of rosiglitazone on angiogenesis are tissue dependent and are determined by its target cells. Our results suggest that, similarly to the adipocyte-mediated proangiogenic effects of rosiglitazone in fat tissue, promotion of angiogenesis in arterial tissue by rosiglitazone and lesion-derived PPAR-␥ agonists requires them to act through SMCs. This implies subendothelial accumulation and/or convection of rosiglitazone or lesion-derived lipids toward the medial layer, which probably is impaired by the endothelial barrier in the static mouse aortic ring angiogenesis assay but could be favored in vivo by factors such as endothelial dysfunction and hypertension.
In conclusion, we show that lesion-derived PPAR-␥ lipid agonists trigger a sustained increase in VEGF-A production by medial SMCs, thus stimulating their proangiogenic activity, and propose that this mechanism could contribute to the increased intramedial neovascularization and VEGF-A production in early human atheromatous aortas.
